Evidence map›Paper›PMID 33690674›Full record

ArticlePloS one2021

Impact of ceftriaxone and temocillin on fecal abundance of extended-spectrum β-lactamase producing Escherichia coli in a mouse model.

Rachel Chenouard, Rafael Mahieu, David Luque Paz, Estelle Marion, Matthieu Eveillard, Vincent Dubée

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Rachel ChenouardMicrobiology Laboratory, Angers University Hospital, Angers, France.
Rafael MahieuCenter for Research in Cancerology and Immunology Nantes-Angers, UMRS1232, Institut National de la Santé et de la Recherche Médicale, Université de Nantes, Université d'Angers, Angers, France.
David Luque PazCenter for Research in Cancerology and Immunology Nantes-Angers, UMRS1232, Institut National de la Santé et de la Recherche Médicale, Université de Nantes, Université d'Angers, Angers, France.
Estelle MarionCenter for Research in Cancerology and Immunology Nantes-Angers, UMRS1232, Institut National de la Santé et de la Recherche Médicale, Université de Nantes, Université d'Angers, Angers, France.ORCID 0000-0003-4917-9665
Matthieu EveillardMicrobiology Laboratory, Angers University Hospital, Angers, France.
Vincent DubéeCenter for Research in Cancerology and Immunology Nantes-Angers, UMRS1232, Institut National de la Santé et de la Recherche Médicale, Université de Nantes, Université d'Angers, Angers, France.ORCID 0000-0002-9982-4741
Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGut colonization by ESBL-producing Enterobacteriaceae (ESBL-PE) is widespread and is promoted by antibiotic exposure. Higher fecal abundance of ESBL-PE promotes the dissemination of the bacteria in the environment and is associated with increased risk of infection. Ceftriaxone and temocillin are commonly used antibiotics with a different activity on gut flora. Their impact on fecal abundance of ESBL-producing Enterobacteriaceae has not been studied. The objective of this study was to compare the propensity of ceftriaxone and temocillin to modify the abundance of ESBL-producing Escherichia coli in feces of colonized mice.

methodsMice received broad-spectrum antibiotics in order to disrupt their normal gut flora. A CTX-M-type ESBL-producing E. coli clinical isolate was then administered orally, leading to durable colonization. Thirty days later, mice received either temocillin or ceftriaxone with drinking water at a concentration simulating human intestinal exposure. Third-generation-cephalosporin resistant (3GCR) E. coli were enumerated in feces on selective medium before, 2 days and 10 days after the end of antibiotic exposure. The experiment was performed with two E. coli isolates with different temocillin minimum inhibitory concentrations.

resultsExposure to ceftriaxone induced an increase in the fecal abundance of 3GCR E. coli. In contrast, temocillin had no effect or transiently decreased the number of 3GCR E. coli. Results obtained with the two strains were similar.

conclusionContrary to ceftriaxone, temocillin does not promote expansion of ESBL-producing E. coli in feces of colonized mice. Thus temocillin may be a therapeutic of choice when a temocillin-susceptible strain infection is suspected or proven to prevent the expansion of ESBL-PE in a previously colonized patient.

Indexed as

AnimalsAnti-Bacterial Agentsbeta-LactamasesCeftriaxoneDisease Models, AnimalEnterobacteriaceaeEscherichia coliEscherichia coli InfectionsFecesFemaleHumansMaleMiceMicrobial Sensitivity TestsPenicillinsAnti-Bacterial Agentsbeta-LactamasesCeftriaxonePenicillinstemocillin

Identifiers

PMID33690674
PMCPMC7946171
OpenAlexW3134130577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.